Sands Capital has closed its latest life sciences investment fund, a $555 million haul that could help support biotechnology companies preparing to go public.
The fund announced Tuesday, named Sands Capital Life Sciences Pulse Fund III, is the firm’s third since forming a life sciences-focused initiative, “Pulse,” in 2018. Sands Capital has now secured $1.3 billion towards the effort, including a similar-sized fund that closed in 2021. It’ll continue to invest in a variety of healthcare companies, from drug and diagnostics developers to the makers of medical devices and life sciences tools.
